Volume : 09, Issue : 12, December – 2022
Title:
66.FORMULATION AND INVITRO EVALUATION OF LOSARTAN POTASSIUM OSMATIC CONTROLLED MATRIX TABLETS
Authors :
H. Padmalatha
Abstract :
The aim of the present study was to develop a controlled porosity osmotic tablet of Losartan potassium and to evaluate the in vitro release of the drug from the system. The osmotic tablet is developed such that it delivers 8 mg of Losartan potassium over a period of 24 hours. Drug – Excipient compatibility study was carried out using FTIR study. The results showed that there was no interaction between them. Calibration curves of Losartan potassium were constructed in three different pH; Acid buffer pH 1.2, Acetate buffer pH 4.5 and phosphate buffer pH 6.8. Wet granulation produced excellent flow and the granules were compressed on 9/32 concave punches into tablets. The tablets were then coated with a controlled porosity semipermeable membrane of CA with sorbitol as pore former. The post compression parameters namely uniformity of weight, thickness, diameter, hardness, drug content and uniformity of content were evaluated for the coated and uncoated tablets and were found to be within limits. To describe the mechanism of drug release, the optimized formulation was fitted to various models. The drug release was found to follow zero order and Hixson Crowell release. The accelerated stability testing was carried out for 3 months and showed no change in the appearance, hardness, diameter, thickness, friability, drug content and in vitro release.
Key words: Formulation, Evaluation, Losartan potassium, Osmatic controlled, matrix tablets
Cite This Article:
Please cite this article in press H. Padmalatha , Formulation And Invitro Evaluation Of Losartan Potassium Osmatic Controlled Matrix Tablets., Indo Am. J. P. Sci, 2022; 09(12).
Number of Downloads : 10
References:
2. Parashar T., Singh V., Singh G., Tyagi S., Patel C., Gupta A. Novel Oral Sustained Release Technology: A Concise Review. Int. J. Res. Dev. Pharm. Life Sci. 2013;2:262–269. [Google Scholar]
3. Khan K.A., Khan G.M., Jan A.U., Mehsud S. Formulation and in vitro evaluation of directly compressed controlled release tablets designed from the Co-precipitates. Pak. J. Pharm. Sci. 2018;31:455–461. [PubMed] [Google Scholar]
4. Varma M.V.S., Kaushal A.M., Garg A., Garg S. Factors Affecting Mechanism and Kinetics of Drug Release from Matrix Based Oral Controlled Drug Delivery Systems. Am. J. Drug Deliv. 2004;2:43–57. doi: 10.2165/00137696-200402010-00003. [CrossRef] [Google Scholar]
5. Kumar K.P.S., Bhowmik D., Dutta A., Paswan S., Deb L. Recent Trends in Scope and Opportunities of Control Release Oral Drug Delivery Systems. Crit. Rev. Pharm. Sci. 2012;1:21–33. [Google Scholar]
6. Uma U., Rathore K.S. Formulation and Evaluation of Sustained Release Matrix Tablets of Metformin Hydrochloride. Pharm. Chem. J. 2014;1:5–13. [Google Scholar]
7. Bakhsh S., Khan G.M., Menaa F., Khan B.A. Design and Evaluation of Matrix Based Controlled Release Tablets of Flurbiprofen. Lat. Am. J. Pharm. 2014;33:1297–1304. [Google Scholar]
8. Swaleh M.M., Syed I.A.Z., Maqsood M.A., Shehnaz S. A Detailed Review on Oral Controlled Release Matrix Tablets. Int. J. Pharm. Sci. Rev. Res. 2020;64:27–38. [Google Scholar]
9. Ali W., Badawi A.A., Mahdy M.A., El-Nahas H.M. Formulation and Evaluation of Carbamazepine 200 mg Controlled Release Tablets Using Different HPMC Grades. Br. J. Pharm. Res. 2013;3:632–647. doi: 10.9734/BJPR/2013/3923. [CrossRef] [Google Scholar]
10. Ige P., Swami B., Patil T., Pradhan J., Patil P., Nerkar P., Surana S.J. Design and Development of Sustained Release Swelling Matrix Tablets of Glipizide for Type II Diabetes Mellitus. Farmacia. 2013;61:883–900. [Google Scholar]
11. Khairnar G., Naik J., Mokale V. A Statistical study on the development of micro particulate sustained drug delivery system for Losartan potassium by 32 factorial design approach. Bull. Fac. Pharm. Cairo Univ. 2017;55:19–29. doi: 10.1016/j.bfopcu.2016.10.001. [CrossRef] [Google Scholar]
12. Khan K.A., Khan G.M., Danish M.Z., Khan H., Rehman F., Mehsud S. Formulation and in-vitro evaluation of directly compressed controlled release matrices of Losartan Potassium using Ethocel Grade 100 as rate retarding agent. Int. J. Pharm. 2015;496:759–765. doi: 10.1016/j.ijpharm.2015.10.051. [PubMed] [CrossRef] [Google Scholar]
13. Gollapudi R., Javvaji H., Tadikonda R.R., Arpineni V. Formulation and In-vitro Evaluation of Sustained Release Matrix Tablets of Losartan Potassium. Pharmanest. 2011;2:31–36. [Google Scholar]
14. Muralidharan S., Meyyanathan S.N., Kumar J., Dhanaraj S.A. In-Vivo Evaluation of Newly Developed Losartan Potassium Sustained Release Dosage form Using Healthy Male Indian Volunteers. Int. J. Drug Deliv. 2012;4:31–43. [Google Scholar]
15. Azharuddin M., Kamath K., Panneerselvam T., Pillai S.S., Shabaraya A.R. Formulation and Evaluation of Controlled Release Matrix Tablets of Antihypertensive Drug Using Natural and Synthetic Hydrophilic Polymers. Res. Biotechnol. 2011;2:26–32. [Google Scholar]
16. Ahad H.A., Kumar C.S., Yesupadam P., Harika B., Deepika D., Leela L.V., Chandra S.A. Formulation and Evaluation of Once-Daily Sustained Release Aceclofenac Prosophis Juliflora Gum Matrix Tablets. Int. J. Pharm. Sci. Rev. Res. 2010;1:23–28. [Google Scholar]
17. Shanmugam S., Chakrahari R., Sundaramoorthy K., Ayyappan T., Vetrichelvan T. Formulation and Evaluation of Sustained Release Matrix Tablets of Losartan potassium. Int. J. PharmTech Res. 2011;3:526–534. [Google Scholar]
18. Nayak N.V.K., Kotade K.B., Gaware V.M., Dolas R.T., Dhamak K.B., Somwanshi S.B., Khadse A.N., Kashid V.A. Eudragit A Versatile Polymer: A Review. Pharmacol. Online. 2011;1:152–164. [Google Scholar]